The Prospective Registry of MyositIS (PROMIS): I. Next-generation sequencing identifies HLA-DQA1 as a novel genetic risk of anti-MDA5 antibody-positive dermatomyositis
Annals of the Rheumatic Diseases · 2025
DOI: 10.1016/j.ard.2025.02.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2025. Verfasst von Xinzhuang Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical …. Hauptthemen laut MEDLINE: Dermatomyositis, Interferon-Induced Helicase, IFIH1, HLA-DQ alpha-Chains, Autoantibodies. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Key Research and Development Program of China, Peking Union Medical College Hospital.
Abstract (Originalsprache)
OBJECTIVES: Antimelanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5+ DM) is a rare subtype of myositis with a poor prognosis and insufficient genetic understanding. Our study aimed to identify risk variants associated with anti-MDA5+ DM and to assess their correlation with clinical outcomes. METHODS: We enrolled 231 anti-MDA5+ DM patients, 127 anti-MDA5⁻ DM patients, 1468 patients with non-DM rheumatic disease, and 1027 healthy controls, with an additional 51 anti-MDA5+ DM patients for validation. Whole-exome sequencing was used to identify human leukocyte antigen (HLA) alleles, amino acids, and single nucleotide polymorphisms (SNPs) in major histocompatibility complex (MHC) and non-MHC regions. Association studies were performed to identify genetic variants associated with anti-MDA5+ DM by comparing different sets of control groups. A clinical association study was conducted to further explore the influence of genetic factors on clinical manifestations. RESULTS: Two novel genetic risks, HLA-DQA1*06:01 and HLA-DQB1*06:09, were significantly associated with anti-MDA5+ DM in both the discovery and validation cohorts. HLA-DQA1*06:01 was particularly prevalent in anti-MDA5+ DM (20.4%) compared with anti-MDA5⁻ DM (6.69%) and non-DM rheumatic disease (5.93%). Besides, the strongest associated amino acid was HLA-DQα1:69 (P = 3.27 × 10-11), and 1 SNP in the ARHGAP22 gene (rs76208937) showed suggestive significance (P = 7.99 × 10-6). In addition, HLA-DQA1*06:01 was linked to acute rapidly progressive interstitial lung disease (P < .001), elevated levels of lactate dehydrogenase (P = .026), and death (P = .049) in patients with anti-MDA5+ DM. CONCLUSIONS: HLA-DQA1*06:01 is a new genetic and prognostic factor for anti-MDA5+ DM, potentially serving as a biomarker for early diagnosis and intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immun…
- Department of Rheumatology and Immunology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
- Medical Intensive Care Unit, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Program of China
- Peking Union Medical College Hospital
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
Zitieren
APA
Yang, X., Yu, C., Zhang, X., Wu, C., Peng, Z., Gai, Y., Peng, J., Zhou, S., Song, L., Huang, H., Xu, D., Zhao, J., Tian, X., Duan, X., Zeng, X., Li, M., & Wang, Q. (2025). The Prospective Registry of MyositIS (PROMIS): I. Next-generation sequencing identifies HLA-DQA1 as a novel genetic risk of anti-MDA5 antibody-positive dermatomyositis. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.02.017
Vancouver
Yang X, Yu C, Zhang X, Wu C, Peng Z, Gai Y, et al. The Prospective Registry of MyositIS (PROMIS): I. Next-generation sequencing identifies HLA-DQA1 as a novel genetic risk of anti-MDA5 antibody-positive dermatomyositis. Annals of the Rheumatic Diseases. 2025. doi:10.1016/j.ard.2025.02.017
BibTeX
@article{Yang2025,
author = {Yang, Xinzhuang and Yu, Chen and Zhang, Xiuling and Wu, Chanyuan and Peng, Zhao and Gai, Yixuan and Peng, Jinmin and Zhou, Shuang and Song, Lan and Huang, Hui and Xu, Dong and Zhao, Jiuliang and Tian, Xinping and Duan, Xinwang and Zeng, Xiaofeng and Li, Mengtao and Wang, Qian},
title = {The Prospective Registry of MyositIS (PROMIS): I. Next-generation sequencing identifies HLA-DQA1 as a novel genetic risk of anti-MDA5 antibody-positive dermatomyositis},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
doi = {10.1016/j.ard.2025.02.017}
}
EUVIMED